← Browse by Condition
Medical Condition

pancreatic adenocarcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for pancreatic adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for pancreatic adenocarcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for pancreatic adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic adenocarcinoma?
pancreatic adenocarcinoma research spans Phase 1 (1 trial), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic adenocarcinoma clinical trial?
Eligibility criteria for pancreatic adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
4
Phase 3
1
Top Sponsors
Kochi University 1 trial
Mayo Clinic 1 trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 trial
Liu Huang 1 trial

Recruiting Clinical Trials

NCT05268692 Phase 2, Phase 3
Recruiting
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Enrollment
500 pts
Location
Japan
Sponsor
Kochi University
View Trial →
NCT04605913 Phase 1, Phase 2
Recruiting
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Enrollment
40 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06789679 Phase 2
Recruiting
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Enrollment
128 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT06199895 Phase 2
Recruiting
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Enrollment
25 pts
Location
China
Sponsor
Liu Huang
View Trial →

Related Conditions

pancreas cancer (1) metastatic pancreatic cancer (1) metastatic adenocarcinoma (1) cholangiocarcinoma (1) lung cancer (1) stomach cancer (1) esophageal carcinoma (1) breast cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology